The bioactivity of Hericium erinaceus is concentrated in two structurally distinct, anatomically separated families of secondary metabolites: erinacines, produced in the mycelium, and hericenones, produced in the fruiting body. Both stimulate nerve growth factor synthesis. Neither has been studied for long. Highland's process is built around quantifying both.
(+)-Erinacin A · A cyathane diterpenoid xyloside, first isolated from Hericium erinaceus mycelia by Kawagishi and colleagues in 1994.
Erinacine A is the most studied of the diterpenoid xylosides produced by Lion's Mane mycelium and the headline compound of the erinacine family. The structure is built around a fused 5–6–7 tricyclic cyathane core — itself uncommon in natural products — with a D-xylopyranosyl sugar attached at the C-15 position and an aldehyde functional group at C-11.
What makes the compound interesting at a pharmacological level is not the carbon skeleton but the way that skeleton allows passage. Erinacine A is small enough and lipophilic enough to cross the blood-brain barrier intact — a property that distinguishes it from the bulk of nutraceutical actives, most of which are excluded by the BBB or extensively metabolized before reaching the CNS. In vivo rodent work has consistently shown that orally administered erinacine A reaches measurable concentrations in brain tissue.
Once present in the CNS, erinacine A has been shown to stimulate the biosynthesis of nerve growth factor (NGF) in cultured astrocytes and to upregulate the NGF–TrkA signaling cascade in animal models. Newer mechanistic work points to activation of the Nrf2 antioxidant pathway and to attenuation of amyloid-β plaque deposition in transgenic Alzheimer's models. The compound is structurally and biologically novel; the literature is still being written.
Direct NGF supplementation is not bioavailable orally. Erinacine A's interest as a nutraceutical compound is that it appears to upregulate endogenous NGF biosynthesis — particularly in astrocytes, the supporting cells of the nervous system — rather than acting as NGF itself.
Following oral administration, erinacine A appears in plasma within hours and reaches measurable concentrations in CNS tissue. The compound's small size and lipophilic character allow passage through the BBB intact.
In cultured astrocytes, erinacine A upregulates NGF mRNA expression and increases NGF secretion. The effect is dose-dependent and reversible on washout — consistent with transcriptional regulation rather than structural binding.
Elevated NGF binds the TrkA receptor on neighboring neurons, activating downstream PI3K/Akt and MAPK signaling. Reported downstream effects include neurite outgrowth, enhanced synaptic plasticity, and attenuation of oxidative damage.
Aromatic meroterpenoids of the resorcinol class, isolated from fruiting bodies of Hericium erinaceus — characterized by Kawagishi et al., 1991, with structural elaboration ongoing.
Hericenones differ from erinacines in almost every respect. They are aromatic rather than aliphatic. They originate in the fruiting body rather than the mycelium. Their core is a 3,5-dihydroxybenzaldehyde resorcinol decorated with a long fatty acid side chain — palmitoyl in hericenone C, stearoyl in hericenone D — esterified at the C-4 hydroxyl.
This architecture — a small aromatic head, a long lipid tail — is what gives hericenones their unusual lipid solubility and their susceptibility to lipase activity. Recent metabolic studies have shown that hericenone C is enzymatically cleaved to deacylhericenone by pancreatic lipase, suggesting the active species in vivo may be the desacyl metabolite rather than the parent compound.
Hericenones C, D, and E stimulate NGF biosynthesis in vitro at micromolar concentrations and have been proposed as part of the cognitive-mechanism story alongside erinacines. The pathways are not identical: hericenones appear to act preferentially through BDNF (brain-derived neurotrophic factor) upregulation in addition to NGF, while erinacines are more selectively NGF-directed. The relative contribution of each family to the whole-extract effect is an open research question.
Highland identifies and quantifies the key bioactive compounds in every production lot using reversed-phase ultra-high-performance liquid chromatography (UHPLC) with UV detection at 270 nm. The method resolves the principal hericenones and erinacines as discrete peaks under a single isocratic-to-gradient run, with characteristic retention times that match published methods for the species.
Sample preparation is by sonication-assisted methanolic extraction from a representative homogenized aliquot of each lot. Identification is confirmed by retention-time matching and UV spectral comparison against authenticated reference standards. Quantification is by external calibration. Reported limits of quantification are at single-digit micrograms per milliliter for the primary compounds.
Every Certificate of Analysis we issue includes the chromatogram, the peak areas, the calculated concentrations of the targeted compounds, and the method parameters. Method validation follows ICH Q2(R1) guidelines for linearity, accuracy, precision, and specificity. The full method file is available under NDA to formulators evaluating Highland material.
The structures shown on this page were first elucidated within the last three decades. Many of the bioassays cited remain preliminary, conducted at cellular or animal-model scale, with human clinical work catching up only recently. New erinacenes and hericenones continue to be reported in the peer-reviewed literature year over year.
Highland's role in this work is small and specific. We cultivate. We extract. We measure. We document what is present in the material we ship — by compound, by lot, by certificate — and leave the science of what those compounds do, downstream, to the literature.
Tech sheets include method parameters, characteristic retention times, and typical compound concentration ranges. Procurement and quality teams running formal qualification can also request the complete Technical Dossier — validated methods, recent COAs, facility documentation, and corporate setup — under mutual NDA.